Evers M, Brandl B, Rohrandt C, Kubelt-Kwamin C, Muller F, Danso D
Comput Struct Biotechnol J. 2024; 26:51-57.
PMID: 39606159
PMC: 11600771.
DOI: 10.1016/j.csbj.2024.11.007.
Buzova D, Petrilli L, Frohlich J, Tsoneva D, Bianco S, Braghini M
Mol Diagn Ther. 2024; 29(1):129-141.
PMID: 39514166
DOI: 10.1007/s40291-024-00754-6.
dAmati A, Bargiacchi L, Rossi S, Carai A, Bertero L, Barresi V
Front Mol Neurosci. 2024; 17:1268038.
PMID: 38544524
PMC: 10966132.
DOI: 10.3389/fnmol.2024.1268038.
Kardian A, Mack S
Dev Neurosci. 2024; 46(6):365-372.
PMID: 38527429
PMC: 11614414.
DOI: 10.1159/000537694.
Ryba A, Ozdemir Z, Nissimov N, Honikl L, Neidert N, Jakobs M
Neuro Oncol. 2024; 26(8):1479-1493.
PMID: 38507506
PMC: 11300017.
DOI: 10.1093/neuonc/noae061.
The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study.
Di Nunno V, Lombardi G, Simonelli M, Minniti G, Mastronuzzi A, Di Ruscio V
J Neurooncol. 2024; 167(1):145-154.
PMID: 38457090
DOI: 10.1007/s11060-024-04589-3.
Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology.
Godicke S, Kresbach C, Ehlert M, Obrecht D, Altendorf L, Hack K
Acta Neuropathol. 2024; 147(1):23.
PMID: 38265527
PMC: 10808473.
DOI: 10.1007/s00401-023-02682-x.
Targeting diffuse midline gliomas: The promise of focused ultrasound-mediated blood-brain barrier opening.
Martinez P, Green A, Borden M
J Control Release. 2023; 365:412-421.
PMID: 38000663
PMC: 10842695.
DOI: 10.1016/j.jconrel.2023.11.037.
MRI-guided focused ultrasound blood-brain barrier opening increases drug delivery and efficacy in a diffuse midline glioma mouse model.
Martinez P, Nault G, Steiner J, Wempe M, Pierce A, Brunt B
Neurooncol Adv. 2023; 5(1):vdad111.
PMID: 37795179
PMC: 10547466.
DOI: 10.1093/noajnl/vdad111.
Ceruloplasmin is associated with the infiltration of immune cells and acts as a prognostic biomarker in patients suffering from glioma.
Jia M, Dong T, Cheng Y, Rong F, Zhang J, Lv W
Front Pharmacol. 2023; 14:1249650.
PMID: 37637428
PMC: 10450624.
DOI: 10.3389/fphar.2023.1249650.
OpenPBTA: The Open Pediatric Brain Tumor Atlas.
Shapiro J, Gaonkar K, Spielman S, Savonen C, Bethell C, Jin R
Cell Genom. 2023; 3(7):100340.
PMID: 37492101
PMC: 10363844.
DOI: 10.1016/j.xgen.2023.100340.
Shining a light on the dark proteome: Non-canonical open reading frames and their encoded miniproteins as a new frontier in cancer biology.
Posner Z, Yannuzzi I, Prensner J
Protein Sci. 2023; 32(8):e4708.
PMID: 37350227
PMC: 10357943.
DOI: 10.1002/pro.4708.
Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer.
Hikmet F, Rassy M, Backman M, Mear L, Mattsson J, Djureinovic D
Mol Oncol. 2023; 17(12):2603-2617.
PMID: 37341056
PMC: 10701773.
DOI: 10.1002/1878-0261.13474.
ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
Jackson E, Duchatel R, Staudt D, Persson M, Mannan A, Yadavilli S
Cancer Res. 2023; .
PMID: 37145169
PMC: 10345962.
DOI: 10.1158/0008-5472.CAN-23-0186.
Pediatric brain tumors: A neuropathologist's approach to the integrated diagnosis.
Viaene A
Front Pediatr. 2023; 11:1143363.
PMID: 36969278
PMC: 10030595.
DOI: 10.3389/fped.2023.1143363.
Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes.
Ajuyah P, Mayoh C, Lau L, Barahona P, Wong M, Chambers H
Sci Rep. 2023; 13(1):3775.
PMID: 36882456
PMC: 9992705.
DOI: 10.1038/s41598-023-30395-4.
Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
Pun M, Pratt D, Nano P, Joshi P, Jiang L, Englinger B
Acta Neuropathol Commun. 2023; 11(1):25.
PMID: 36759899
PMC: 9912509.
DOI: 10.1186/s40478-023-01514-z.
Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
Lopez-Perez C, Franco-Mojica X, Villanueva-Gaona R, Diaz-Alba A, Rodriguez-Florido M, Garcia Navarro V
J Neurooncol. 2022; 158(3):369-378.
PMID: 35567713
DOI: 10.1007/s11060-022-04024-5.
Molecular subtyping of ependymoma and prognostic impact of Ki-67.
Lim K, Lee K, Shim Y, Park J, Kim H, Kang J
Brain Tumor Pathol. 2021; 39(1):1-13.
PMID: 34812989
PMC: 8752536.
DOI: 10.1007/s10014-021-00417-y.
H3.3K27M Mutation Controls Cell Growth and Resistance to Therapies in Pediatric Glioma Cell Lines.
Rakotomalala A, Bailleul Q, Savary C, Arcicasa M, Hamadou M, Huchede P
Cancers (Basel). 2021; 13(21).
PMID: 34771714
PMC: 8583077.
DOI: 10.3390/cancers13215551.
